Antibodies to high mobility group-1(HMGB1) B-box polypeptides
View Patent ↗Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to a B-box fragment of high mobility group B 1 (HMGB1) wherein the B-box fragment: (i) stimulates release of a proinflammatory cytokine selected from the group consisting of TNF, IL-1β, IL-6 and a combination thereof, from a vertebrate cell selected from the group consisting of a macrophage, a monocyte, a neutrophil and a combination thereof and (ii) consists of the amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:23, a fragment of SEQ ID NO: 16, and a fragment of SEQ ID NO: 23, wherein the antibody or antigen-binding fragment inhibits HMGB1-mediated release of a proinflammatory cytokine selected from the group consisting of TNF, IL-1β, IL-6 and a combination thereof from a vertebrate cell selected from the group consisting of a macrophage, a monocyte, a neutrophil and a combination thereof.
2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-biding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.
3. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.
4. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.
5. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment thereof is a human monoclonal antibody or an antigen-binding fragment thereof, or a humanized monoclonal antibody or an antigen-binding fragment thereof.
6. The antibody of claim 1 wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a chimeric antibody, a single chain antibody and an Fab antibody fragment.
7. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable excipient.
8. The composition of claim 7 , further comprising an antagonist of an early sepsis mediator, wherein the antagonist of an early sepsis mediator is an antibody to TNF or MIF, or an IL-1 receptor antagonist.
9. An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to a B-box fragment of high mobility group B 1 (HMGB1) wherein the B-box fragment: (i) stimulates release of a proinflammatory cytokine selected from the group consisting of TNF, IL-1β, IL-6 and a combination thereof from a vertebrate cell selected from the group consisting of a macrophage, a monocyte, a neutrophil and a combination thereof, and (ii) consists of the amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:23, a fragment of SEQ ID NO: 16, and a fragment of SEQ ID NO: 23, wherein the antibody or antigen-binding fragment inhibits HMGB1-mediated release of a proinflammatory cytokine selected from the group consisting of TNF, IL-1β, IL-6 and a combination thereof from a vertebrate cell selected from the group consisting of a macrophage, a monocyte, a neutrophil and a combination thereof.
10. An isolated antibody or antigen-binding fragment thereof that specifically binds to a polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NO:16 and SEQ ID NO:23.